121 completed, 32 unknown, 16 terminated, 11 recruiting. 189 Phase 2, 24 Phase 3, 15 Phase 1.
Follow Vomiting: new trials by email Literature Review of Vomiting trials Research Report on Vomiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-11-02 | 2026-11-05 |
| Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera Ondansetron, Standard Cholera Care - Cholera (Disorder) | Phase 2 | Not yet recruiting | Public Interest Science Center | 120 | 2026-10-20 | 2026-10-19 |
| Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Chinese Herbal Acupoint Application, Sham Acupoint Application, Standard Triple Antiemetic Therapy - Breast Neoplasms | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2026-10-01 | 2026-09-30 |
| A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting HRS5580 for injection combined with palonosetron hydrochloride;, HRS5580 for injection combined with palonosetron hydrochloride, HRS5580 for injection blank preparation combined with palonosetron hydrochloride - Prevention of Postoperative Nausea and Vomiting | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 260 | 2026-08-06 | 2026-08-26 |
| Hyperemesis Gravidarum Risk Reduction With Metformin Metformin Extended Release Oral Tablet - Hyperemesis Gravidarum | Phase 1 / Phase 2 | Recruiting | University of Southern California | 224 | 2026-07-13 | 2026-07-22 |
| Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV Fosrolapitant and Palonosetron Hydrochloride for Injection - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-06-15 | 2026-07-24 |
| Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin dexamethasone sparing - Cancer (Solid Tumors), Vomiting | Phase 2 | Recruiting | Mahidol University | 95 | 2026-02-10 | 2026-07-13 |
| Midazolam Adjunct Therapy for Prevention of PONV in Gynecological Laparoscopy Midazolam 0.05 mg/kg IV as adjunct to dexamethasone and ondansetron for PONV prevention - Postoperative Nausea and Vomiting (PONV), Gynecological Laparoscopic Surgery | Phase 2 | Completed | Hameed Latif Hospital, Lahore | 300 | 2025-12-02 | 2026-06-25 |
| Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting nanocrystalline megestrol acetate combined with ondansetron, dexamethasone combined with ondansetron - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 2 | Not yet recruiting | AIPING ZHOU | 127 | 2025-12-01 | 2025-11-24 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer LY3537021, Placebo, Standard of Care Antiemetic Therapies - Nausea, Vomiting | Phase 2 | Recruiting | Eli Lilly and Company | 204 | 2025-11-28 | 2026-11-04 |
| Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion - Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy | Phase 2 | Recruiting | Helsinn Healthcare SA | 95 | 2025-07-07 | 2026-09-29 |
| Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery Encapsulated amisulpride 50 mg (matched for color, weight, smell and size), Encapsulated placebo (matched for color, weight, smell and size) - Post Operative Nausea and Vomiting (PONV) | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 276 | 2025-04-10 | 2026-09-09 |
| Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Aprepitant, Placebo - Spinal Fusion, Nausea and Vomiting, Postoperative | Phase 2 | Recruiting | IWK Health Centre | 100 | 2025-03-17 | 2026-04-27 |
| A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use Tradipitant, Placebo - Obesity | Phase 2 | Completed | Vanda Pharmaceuticals | 124 | 2025-02-25 | 2025-11-12 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg - Idiopathic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 416 | 2025-01-29 | 2026-07-13 |
| Effect of Magnesium Sulfate on Hemodynamics on Laparoscopic Cholecystectomy Patients Placebo, Magnesium - Hemodynamics Instability, Pain After Surgery | Phase 1 / Phase 2 | Completed | Ziauddin University | 60 | 2025-01-06 | 2026-09-02 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive - Postoperative Pain, Nausea and Vomiting, Postoperative | Phase 1 / Phase 2 | Active not recruiting | University of Arizona | 100 | 2024-10-10 | 2026-02-13 |
| Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting HSK21542, Dolasetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 2 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 180 | 2024-09-16 | 2024-09-19 |
| Opioid Free Versus Opioid Balanced Anesthesia in Ophthalmic Surgery Dexmedetomidine, Fentanyl - Anesthesia and Analgesia, Anesthesia, Endotracheal | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 104 | 2024-06-01 | 2024-04-30 |
Showing 20 of 189. Sign in to see all of them.
Nausea (99) · Postoperative Nausea and Vomiting (58) · Pain, Postoperative (14) · Neoplasms (11) · Breast Neoplasms (7) · Abdominal Pain (5) · Gastroparesis (5) · Hyperemesis Gravidarum (5) · Colonic Neoplasms (4) · Pain (4) · Bile Duct Neoplasms (3) · Colorectal Neoplasms (3) · Diarrhea (3) · Fever (3)
Pathological Conditions, Signs and Symptoms (189) · Signs and Symptoms (189) · Signs and Symptoms, Digestive (189) · Pathologic Processes (64) · Postoperative Complications (60) · Nausea (46) · Neoplasms (28) · Neurologic Manifestations (27) · Neoplasms by Site (25) · Pain (19) · Digestive System Diseases (14) · Neoplasms by Histologic Type (13) · Urogenital Diseases (13) · Gastrointestinal Diseases (11)
Ondansetron (35) · Dexamethasone (31) · Aprepitant (27) · Palonosetron (24) · Olanzapine (15) · Granisetron (9) · fosaprepitant (9) · Calcium Dobesilate (7) · Saline Solution (7) · ginger extract (7) · Acupuncture Therapy (4) · Dronabinol (4) · Metoclopramide (4) · netupitant, palosentron drug combination (4) · Dexmedetomidine (3)
GlaxoSmithKline (6) · Acacia Pharma Ltd (4) · M.D. Anderson Cancer Center (4) · Assiut University (3) · Fudan University (3) · Instituto do Cancer do Estado de São Paulo (3) · Merck Sharp & Dohme LLC (3) · National Research Centre of Complementary and Alternative Medicine, Norway (3) · The Hospital for Sick Children (3) · Chinese Academy of Medical Sciences (2) · CinDome Pharma, Inc. (2) · Clinica Universidad de Navarra, Universidad de Navarra (2) · Eisai Inc. (2) · Gary Morrow (2) · Helsinn Healthcare SA (2)
United States (80) · China (16) · Canada (14) · Egypt (10) · Germany (8) · Italy (8) · Brazil (6) · Denmark (6) · Spain (6) · Thailand (6) · France (5) · Pakistan (5) · Poland (5) · United Kingdom (5) · Belgium (4)
Arne Johan Norheim, PhD (2) · Jorge Cortes, MD (2) · Joseph Bubalo, PharmD, BCPS, BCOP (2) · Lee Dupuis, RPh, PhD (2) · Nicola Di Renzo, MD (2) · Roger Chammas (2) · A. Riaz, MD (1) · Aaron P Hong, MD, FRCPC (1) · Agop Y. Bedikian, MD (1) · Ajeet Gajra, MD FACP (1) · Alaa Y. Darwesh, Dr (1) · Alana Koehler, MD (1) · Alfonso Gurpide (1)
PMID 34002866, PMID 12145072, PMID 12906958, PMID 15680647, PMID 16408862, PMID 16436839, PMID 16846542, PMID 17513629, PMID 17885699, PMID 19092351, PMID 19617379, PMID 19834961, PMID 20049561, PMID 20718754, PMID 21851346, PMID 22096279, PMID 22141732, PMID 22286518, PMID 22520120, PMID 22546895, PMID 22546966, PMID 22733373, PMID 23041302, PMID 23510951, PMID 23811424, PMID 23872464, PMID 23904932, PMID 23936162, PMID 24337621, PMID 24438599, PMID 24587006, PMID 24882606, PMID 25127659, PMID 25488303, PMID 25670522, PMID 25834396, PMID 25885838, PMID 26838019, PMID 27082959, PMID 27307177, PMID 27829428, PMID 28032216, PMID 28058142, PMID 28069044, PMID 28160217, PMID 28243404, PMID 28760384, PMID 28856448, PMID 29111115, PMID 30900392
2008 (1), 2009 (1), 2014 (1), 2019 (1), 2025 (1), P30CA046592 (1), P30CA069533 (1), R01HD076313 (1), R21HD105101 (1), U01DK073974 (1), U01DK073975 (1), U01DK073983 (1), U01DK073985 (1), U01DK074007 (1), U01DK074008 (1)